Hayon Igal Louria - 20 Nov 2025 Form 4 Insider Report for Raphael Pharmaceutical Inc. (RAPH)

Reporting relationship: Chief Technology Officer
Issuer ticker: RAPH
Reported as of: 20 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Apr 2026, 18:22:31 UTC
Prior SEC filing: 25 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Hayon Igal Louria

Key filing fact

Hayon Igal Louria filed Form 4 for Raphael Pharmaceutical Inc. (RAPH) on 06 Apr 2026.

Key facts

This page summarizes Hayon Igal Louria's Form 4 filing for Raphael Pharmaceutical Inc. (RAPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2026, 18:22.

Change

Previous filing in this sequence was filed on 25 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001903781 Primary reporting owner

Louria Hayon Igal

Relationship: Chief Technology Officer
Address: 4 LUI PASTER, TEL AVIV-JAFFA, ISRAEL
Signature: /s/ Hayon Igal Louria
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPH transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +350,000
Change %: +35%
Price: $0.0100^*
Shares after: 1,349,000
Date: 20 Nov 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPH transaction Derivative

Warrants to purchase Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -350,000
Change %: -100%
Price
Shares after: 0
Date: 20 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 350,000
Exercise price: $0.0100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table.